Cargando…
Lung cancer screening, what has changed after the latest evidence?
Lung cancer (LC) is still one of the most frequent cancers with a high related mortality. Their prognosis is directly proportional to the stage at the time of diagnosis. Seventy percent are currently diagnosed in advanced or locally advanced stage (higher than stage III), making a cure unlikely for...
Autores principales: | Trujillo-Reyes, Juan Carlos, Seijo, Luis, Martínez-Tellez, Elisabeth, Couñago, Felipe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422527/ https://www.ncbi.nlm.nih.gov/pubmed/32850015 http://dx.doi.org/10.4329/wjr.v12.i7.130 |
Ejemplares similares
-
Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy
por: Aguado, Carlos, et al.
Publicado: (2022) -
Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
por: Sereno, María, et al.
Publicado: (2021) -
Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
por: Sotelo, Miguel J, et al.
Publicado: (2021) -
Current treatment landscape for oligometastatic non-small cell lung cancer
por: Garde-Noguera, Javier, et al.
Publicado: (2022) -
New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2
por: Olmedo, Maria Eugenia, et al.
Publicado: (2022)